In vivo animal models provide valuable information leading to improved understanding of human and animal diseases and development of new medicines, devices, and treatment modalities. While the value of animal models in advancing science and medicines is well established, the scientific community is continually working to identify novel approaches that may lead to improved clinical translation and relevance of animal models. Further, the scientific community is committed to the 3Rs (replacement, reduction, and refinement), which are rapidly evolving as a part of advancing optimal science and animal welfare.
The NA3RsC has three major initiatives where we are seeking participation:
The Microphysiological Systems initiative will include all commercially-available MPS being used in drug discovery/development and will focus on models already translated into use. The goal is to increase the interaction and adoption of MPS technologies, including 3D cell culture assays, spheroids, organoids, tissue-chips, and organs-on-chips to end users.
Translational Digital Biomarkers
The Translational Digital Biomarkers initiative will include early stage and commercially available digital biomarker technologies and will engage end-users and those interested in learning more about how these technologies can be used to promote the 3Rs.
The Refinement Initiative will identify, curate, and promote evidence-based Refinement resources to improve animal welfare and scientific rigor. We will assess the research community for needs, develop a hub of resources, and connect those interested in refinement.